AP NEWS

NantKwest to Present at 2018 Cantor Global Healthcare Conference

October 2, 2018

CULVER CITY, Calif.--(BUSINESS WIRE)--Oct 2, 2018--NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2 nd in New York City During the conference, company management will be presenting a corporate overview, as well as conducting one-on-one meetings to provide a corporate update, as well as review R&D and clinical activities.

Conference Details:

About NantKwest Inc.

NantKwest is an innovative clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.

NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The NantKwest “off-the-shelf” activated Natural Killer (NK) platform has the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005835/en/

CONTACT: NantKwest Inc.

Media Contact:

Jen Hodson

jhodson@nantworks.com

or

Investor Contact:

David Pyrce, 951-551-0949

david.pyrce@nantkwest.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: NantKwest Inc.

Copyright Business Wire 2018.

PUB: 10/02/2018 12:02 PM/DISC: 10/02/2018 12:02 PM

http://www.businesswire.com/news/home/20181002005835/en

AP RADIO
Update hourly